Characterize infections and outcomes developed in relapsed/refractory multiple myeloma (RRMM) patients treated with Teclistamab (SPOT)

Data sources

• Data sources (types):
  Non-interventional study

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Yes
• Check completeness:
  Yes
• Check stability:
  Yes
• Check logical consistency:
  Yes

Data characterisation

• Data characterisation conducted:
  Yes